Clasp

Clasp Therapeutics is a biotechnology company focused on developing next-generation immunooncology drugs called bispecific T cell engagers (TCEs). The company's platform, originating from research at Johns Hopkins University, aims to create off-the-shelf TCE therapies that specifically target common oncogenes in cancer cells without causing toxicity to healthy cells.

Traditional TCEs currently used in the clinic recognize markers expressed on both tumor and normal cells, leading to on-target, off-tumor toxicity. Clasp's approach is to target oncogenes such as p53, KRAS, and PI3 Kinase, which produce cancer-specific peptides presented on the surface of tumor cells in the context of the human leukocyte antigen (HLA) system. By targeting these mutated peptides, Clasp aims to create multiple off-the-shelf versions of TCEs for different HLA phenotypes, enabling personalized treatment for eligible patients based on their tumor's mutation and HLA profile.

This targeted approach is expected to reduce the development of resistance to the therapy, as the targeted oncogenes are central to the tumor's oncogenicity. While Clasp has not announced specific cancer targets, its current focus is on solid tumors. In March 2024, the company launched with USD 150 million in series A financing, intended to support its progression to clinical data before raising additional funds.